Clinical expansion Small, early-stage biotech focusing on transcriptomics and cf-mRNA diagnostics with recent moves toward clinical-grade products for Alzheimer's disease, presenting opportunities to partner on translational studies, contract development, and early diagnostic services.

Strategic partnerships Notable engagement with Verily Life Sciences and a board addition signals openness to collaboration; sales opportunities include joint labs, access to translational platforms, and co-development of cf-mRNA liquid biopsy solutions.

Financial runway Limited revenue under one million with funding of around eight million; potential for grant support, milestone-based partnerships, and phased commercial contracts to sustain development until scale.

Specialized focus Pioneer in cf-mRNA liquid biopsy and Alzheimer's translational studies; potential customers include biopharma for companion diagnostics, clinical trial endpoints, and precision medicine workflows.

Tech & ops readiness Current tech stack includes RT-qPCR and collaboration tools; opportunities to offer assay development, validation services, data analytics, and cloud-based collaboration for joint research programs.